InterAx Biotech helps Sosei Heptares with drug discovery

The British pharmaceutical company Sosei Heptares has agreed a partnership with InterAx Biotech AG. It plans to use the platform of the Aargau-based start-up to research new drugs, with a focus on a G protein-coupled receptor.

InterAx Biotech is based in PARK innovAARE in Villigen. Image credit: Markus Teller
InterAx Biotech is based in PARK innovAARE in Villigen. Image credit: Markus Teller

Sosei Heptares and InterAx Biotech AG have agreed a research and development partnership, according to a press release. The British pharmaceutical company plans to use the platform produced by the Aargau-based start-up to carry out a more detailed study of a G protein-coupled receptor (GPCR) that has been linked to inflammatory diseases. GPCRs transmit signals from extracellular substances to the cell interior, where they trigger a response. These responses can be analyzed using InterAx’s platform.

Of around 800 known GPCRs, approximately 370 are of interest as docking sites for medications. However, according to an earlier press release issued by the Swiss Federal Institute of Technology in Zurich (ETH), it has so far only been possible to use one in six of these for pharmacological purposes. InterAx Biotech’s platform will make it possible to find out more quickly and efficiently which GPCRs are relevant for medications. InterAx also plans to inform a future Sosei Heptares drug design program through the partnership.

InterAx Biotech is a spin-out of ETH Zurich and the Paul Scherrer Institute (PSI). Its platform is based on tools including artificial intelligence and cell signaling technology. 

Handbook for Investors

Our Handbook for Investors provides valuable information about technologies and production costs, taxes and financing, as well as the legal system and infrastructure in Switzerland. Browse through the complete handbook online or download the chapters most relevant to you.


Official program